Julia Tao

Julia Tao

Auto-generated profile, based on publicly available information

Julia Tao

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
HTHsin-Fang Tu
Hsin-Fang Tu
JTJulia Tao
Julia Tao
MHMing Hung Hu
Ming Hung Hu
DFDarrell Fan
Darrell Fan
YTYa-Chea Tsai
Ya-Chea Tsai
CHChien-Fu Hung
Chien-Fu Hung
Background: Ly6C expression in naïve CD8+ T cells plays a crucial role in enhancing their effector activity, suggesting potential implications for cancer immunotherapy. This study investigates the functional impact of Ly6C expression on CD8+ T cells and explores albumin-conjugated IFNβ (Alb-IFNβ) as a strategy to modulate Ly6C expression and improve cancer vaccine efficacy. Methods: We analyzed the functional differences between Ly6C high-expressing (Ly6Chi) and Ly6C low-expressing (Ly6Clo) naïve CD8+ T cells in tumor suppression. To assess the role of type I interferon signaling, we administered Alb-IFNβ in C57BL/6J and IFNAR−/− mice and measured Ly6C expression in CD8+ T cells. The therapeutic potential of Alb-IFNβ was further evaluated in combination with a vaccinia virus encoding the HPV-16 E7 antigen (CRT-E7 vaccine) in a syngeneic TC-1 tumor model, assessing tumor growth, survival, and antigen-specific CD8+ T cell responses. Results: Naïve CD8+ T cells with elevated Ly6C expression exhibited enhanced tumor-suppressive capacity and required lower activation thresholds for effector function. Alb-IFNβ treatment selectively increased Ly6Chi naïve CD8+ T cells in C57BL/6J mice but not in IFNAR−/− mice, confirming type I interferon’s role in Ly6C regulation. Combining Alb-IFNβ pretreatment with the CRT-E7 vaccine significantly enhanced antigen-specific CD8+ T cell immunity, reducing tumor growth and prolonging survival in TC-1 tumor-bearing mice. Conclusions: Our findings suggest that Alb-IFNβ may enhance the antitumor activity of naïve CD8+ T cells by modulating Ly6C expression. Alb-IFNβ could potentially improve the efficacy of HPV vaccinia-based cancer vaccines, warranting further investigation as an adjuvant strategy in cancer immunotherapy.